Amikacin Inhale Shows Promising Results in Phas... (ection without reaching highsystemic con...)

Amikacin Inhale Shows Promising Results in Phase II Study

Date:5/19/2008

ection, without reaching high systemic concentrations."

Amikacin Inhale is a unique drug-device combination, being developed by Bayer HealthCare in cooperation with Nektar Therapeutics, combining a special liquid formulation of the aminoglycoside antibiotic amikacin with Nektar Therapeutics' proprietary Liquid Pulmonary Technology (LPT(TM)), designed to deliver amikacin deep into the infected lungs.

The device can be integrated into mechanical ventilation systems and can also be used as a handheld 'off-vent' device for patients no longer requiring breathing assistance. This allows for a unique full course of drug therapy in critically ill patients with Gram-negative pneumonia. 'Gram-negative pneumonia' refers to pneumonia caused by a laboratory-defined group of pathogens, the Gram-negative bacteria. These account for a substantial proportion, if not the majority of pneumonias in intensive care units (ICUs).

"A challenge in treating Gram-negative pneumonia in ICUs is that they have grown increasingly resistant to currently available antibiotics," said Professor Donald Low, Head of the Department of Microbiology at the Toronto Medical Laboratories and Mount Sinai Hospital, Toronto, Canada. "A new treatment option such as Amikacin Inhale, which fights pneumonia directly at the site of infection, may be able to help decrease resistance -- especially if concomitant intravenous antibiotic therapy can also be reduced."

Amikacin Inhale will enter Phase III trials later this year to further assess its efficacy and safety in mechanically ventilated patients with Gram-negative pneumonia. The enrolment for two pivotal Phase III studies will start in the fourth quarter of 2008.

About Phase II Studies

High Amikacin Lung Deposition in MVP(2)

In the multi-center, randomized, double-blind, placebo-controlled Phase II study mechanically ventilated patients (MVP) received 400 mg doses of amikacin with Amikacin Inhale every 24 hours (n=2
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
2. Inhaled Steriods Used as Preventive Treatment Post 9/11
3. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
4. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
5. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
6. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
7. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
8. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile

Post Your Comments:

(Date:12/16/2009)... According to Millennium Research Group (MRG), the global ... US minimally invasive spinal fusion market will expand ... 12% through 2014, reimbursement concerns in certain segments ... previously had been forecast at almost 20%. ,, ... Technologies 2010 report finds that ...

(Date:12/16/2009)... Dec. 16 Ethicon, Inc., a Johnson ... and a worldwide leader in surgical care, and ... dedicated to designing, developing and commercializing devices that ... (ENT), today announced a definitive merger agreement whereby ... for approximately $785 million net of estimated cash ...

(Date:12/16/2009)... at,deCODE genetics, Inc. (Nasdaq: DCGN ) publish in ... a common single-letter variant in the sequence of,the ... susceptibility to type 2,diabetes (T2D). The impact of ... unusual:,if an individual inherits it from their father, ... 30% compared to those who inherit the non ...

Breaking Medicine Technology:Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 2 Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 3 Ethicon Announces Definitive Agreement to Acquire Acclarent 2 Ethicon Announces Definitive Agreement to Acquire Acclarent 3 Ethicon Announces Definitive Agreement to Acquire Acclarent 4 deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2 deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3 deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4 Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 5616 1 Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 5616 2 Heart Failure Treatment Underused 59853 1 Heart Failure Treatment Underused 59853 2 Fish Oil Supplements Dont Help Depressed Heart Patients 59851 1 Fish Oil Supplements Dont Help Depressed Heart Patients 59851 2 Fish Oil Supplements Dont Help Depressed Heart Patients 59851 3

[0] Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking [0] Ethicon Announces Definitive Agreement to Acquire Acclarent [0] deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin

... of Phase II Study Demonstrates Significant,Additional Improvement ... 12, 2007 /PRNewswire-FirstCall/ --,Indevus Pharmaceuticals, Inc. today ... EXPRESS trial for pagoclone in persistent,developmental stuttering ... annual,meeting of the New Clinical Drug Evaluation ...

... LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - Critical,Therapeutics, Inc. ... a pivotal Phase III clinical trial of ZYFLO ... of the,Journal of Asthma. ZYFLO CR was approved ... May 30, 2007. Critical Therapeutics,together with its co-promotion ...

Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma

(Date:12/17/2009)... marketing techniques, life coaching company puts free i-phone & ... http://itunes.apple.com/us/app/attainment-life-management/id345691804?mt=8 . For the Free download. , ... ... -- Utah based Attainment Life Management & Coaching is ... everything in life simplified into one little hand held ...

(Date:12/16/2009)... -- Austin,s Custom Tops , a local business ... Gray and Hill Country Home Health, a slider-eating throwdown ... 9th. Fifty people showed up to cheer on the ... of sliders in support of the local charity, The ... casual bet over who could eat the most burgers ...

(Date:12/16/2009)... December 16, 2009 -- Every year in the ... and 57,000 patients die of the disease, making it ... adults, after lung cancer. , As researchers and clinicians ... -- simultaneously generating thousands of studies producing more and ... researcher of cancer and genetics at Case Western Reserve ...

(Date:12/16/2009)... Dec. 16 Allscripts (Nasdaq: MDRX ... financial results for the three and six months ... opens on Monday, January 11, 2010. Allscripts management ... discuss the company,s earnings and other information at ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts ...

(Date:12/16/2009)... HealthSciences Institute will sponsor a ... teams and organizations who serve individuals at ... in employer, health plan, medical home and ... offer free, noncommercial webinars on topics, solutions ... management and care improvement. Each webinar will ...

Breaking Medicine News(10 mins):Health News:Attainment Life Management & Coaching has just Debuted its Free Application for I-Phone and I-Touch Users 2 Health News:Austin-Based Business Co-Sponsors Gastric Feat for Charity 2 Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2 Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3 Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2 Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3 Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4 Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2 Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3

[0] Attainment Life Management & Coaching has just Debuted its Free Application for I-Phone and I-Touch Users [0] Austin-Based Business Co-Sponsors Gastric Feat for Charity [1] New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer'[0] Allscripts to Announce Second Quarter Fiscal 2010 Results [1] New Learning Collaborative to Prepare Clinicians for Better Chronic Care

... ingredients are now utilized,in thousands of consumer ... ,tea think-tank, notes that non-beverage,consumer products containing ... a global basis. Tea and "herbal tea" ... being formulated into,thousands of consumer products including, ...

... Laborie Medical Technologies,today announced that the TETRA(TM)-NIRS ... with marketing efforts for this new and,exciting technology ... Drug Administration,(USFDA)., Laborie Medical Technologies is initiating ... (ISO-13485) so that,TETRA(TM) can be made available to ...

... of surgery a patient with kidney cancer receives depends ... tumor size, demographic characteristics, or general medical health. The ... not be receiving the most appropriate surgical care. The ... of CANCER, a peer-reviewed journal of the American Cancer ...

... by the Biotechnology and Biological Sciences Research Council ... Molecular Pharmacology identifying the structure of a receptor ... epilepsy and pre-menstrual tension. The same receptor has ... alcohol. , The University of Cambridge team, in ...

... Major Cities, PHILADELPHIA, March 9 Today Shire ... program for,people with ulcerative colitis (UC), a disease that ... events will feature four,expert presenters and will provide an ... with others who have UC., Experts at each ...

... bullied workers had more stress, less commitment and higher ... -- Persistent criticism, belittling comments, bullying and other forms ... than sexual harassment, according to a Canadian study. ... organizations may be more attuned to helping victims, who ...

Other Medicine News:Health News:Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products 2 Health News:Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products 3 Health News:Laborie Medical Technologies Receives FDA Pre-Market Clearance for TETRA(TM)- NIRS Accessory for the US Market 2 Health News:Kidney cancer surgery often determined by surgeons' practice style, not medical factors 2 Health News:Scientists determine structure of brain receptor implicated in epilepsy and PMT 2 Health News:Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis 2 Health News:Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis 3 Health News:Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis 4 Health News:Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis 5 Health News:Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis 6 Health News:Aggression on Job More Harmful Than Sexual Harassment 2

Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products Laborie Medical Technologies Receives FDA Pre-Market Clearance for TETRA(TM)- NIRS Accessory for the US Market Kidney cancer surgery often determined by surgeons' practice style, not medical factors Scientists determine structure of brain receptor implicated in epilepsy and PMT Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis Aggression on Job More Harmful Than Sexual Harassment

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

Medicine Products:

Lead, Industrial Exposure Panel, Adults LDL Cholesterol, Direct Lasix, Urine Lanoxin

Amikacin Inhale Shows Promising Results in Phas...(ection without reaching highsystemic con...),Health